Modern treatment of short bowel syndrome

PURPOSE OF REVIEWRecently, the US Food and Drug Administration and the European Medicines Agency approved the glucagon-like peptide 2 analogue, teduglutide, for the treatment of short bowel syndrome (SBS), and this review describes the physiological basis for its clinical use. RECENT FINDINGSBy affe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Current opinion in clinical nutrition and metabolic care 2013-09, Vol.16 (5), p.582-587
1. Verfasser:	Jeppesen, Palle B
Format:	Artikel
Sprache:	eng
Schlagworte:	Glucagon-Like Peptide 2 - therapeutic use Humans Intestinal Absorption - drug effects Parenteral Nutrition Peptides - therapeutic use Quality of Life Risk Assessment Short Bowel Syndrome - physiopathology Short Bowel Syndrome - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!